Syngenta grows strongly and stays true to Basel
Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.
Syngenta headquarter in Basel (img: Syngenta)
The agricultural group Syngenta is still staying true to its roots in Basel even after the takeover by Chemchina, as the newly founded Syngenta Group will be headquartered there. In addition to the former Syngenta AG, the group also comprises Adama from Israel and the agricultural business of Sinochem, which is based in China.
Syngenta Group started operating on Thursday according to a press release. The three companies are being connected to create a much larger group. Last year Syngenta, Adama and Sinochem achieved sales of 23 billion US dollars. In comparison, when Chemchina took on Syngenta in 2017 for 43 billion US dollars, the company had achieved sales of just under 13 billion dollars.
According to its own information, Syngenta Group is now the global market leader in crop protection, third place for seeds, and the market leader for fertilizers in China. Overall, it employs 48,000 staff in more than 100 countries.
Erik Fyrwald, former CEO of Syngenta AG, will head up the new group as CEO. He says: “I am pleased that our new organization is ready to bring the diversity and expertise of our teams to deliver the broadest range of sustainable and competitive products.” He goes on to say that the individual business units will be “enhanced” by the collaboration within the group.
Share this article
You may also be interested in
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More